ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Japan approval for remdesivir expected 'soon,' Abe says

Antiviral drug will receive fast-track status if certified by another nation

Prime Minister Shinzo Abe speaks in the Diet parliamentary building in Tokyo on April 27. (Photo by Uichiro Kasai)

TOKYO -- Japan is on the verge of initiating a fast-track approval process for Gilead Sciences' antiviral drug remdesivir to treat patients infected by the novel coronavirus, Prime Minister Shinzo Abe said Monday.

Japan's health ministry will place remdesivir on a shortened authorization track once another nation certifies the drug to treat COVID-19. Results from international clinical trials are expected shortly.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more